A Two Period, 2 Sequence Crossover To Establish The Relative Bioavailability Of A Single Pf-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers.

Trial Profile

A Two Period, 2 Sequence Crossover To Establish The Relative Bioavailability Of A Single Pf-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2011

At a glance

  • Drugs PF 4634817 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 31 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 06 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top